JW (Cayman) Therapeutics Co. Ltd. (2126) AI Stock Analysis

JW (Cayman) Therapeutics Co. Ltd.

(HKEX:2126)

Select Model

Rating:50Neutral

Price Target:HKD 2.00▼(-9.91% Downside)

Action:reiterated

Date:09/23/26

Primarily impacted by subdued financial performance reflecting typical biotech cash burn and losses, offset partially by favorable technical indicators.

Positive Factors

Revenue and gross-margin improvementThe sharp 2025 revenue rebound, alongside improved gross margin, indicates stronger commercialization and better economics for the company’s therapy portfolio. If sustained, this combination can expand operating leverage, support reinvestment in clinical programs, and improve the path toward eventual profitability.

Negative Factors

Deep and persistent unprofitabilityDespite stronger revenue and narrower losses, the company remains far from operating break-even. A deeply negative net margin means commercial growth is not yet translating into sustainable earnings, leaving profitability dependent on further scale, cost improvement, or successful product expansion.

JW (Cayman) Therapeutics Co. Ltd. (2126) vs. iShares MSCI Hong Kong ETF (EWH)

Market Cap: HKD 925.14M
Dividend Yield: ―
Average Volume (3M): 1.55M
Price to Earnings (P/E): -2.4
Beta (1Y): 1.65
Revenue Growth: 67.48%
EPS Growth: 43.84%
Country: Hong Kong
Employees: 303
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

JW (Cayman) Therapeutics Co. Ltd. Business Overview & Revenue Model

Company Description

JW (Cayman) Therapeutics Co. Ltd is a clinical-stage biotechnology company dedicated to the development, manufacture, and commercialization of cell-based immunotherapies. The company primarily targets hematological cancers and solid tumors through tr...

How the Company Makes Money

The company makes money primarily through commercialization of its approved CAR-T therapies, recognizing revenue from product sales to healthcare providers and/or distribution channels where it has marketing authorization. Additional revenue can come...

JW (Cayman) Therapeutics Co. Ltd. Financial Statement Overview

Summary

Despite strong revenue growth, the company faces challenges from persistent unprofitability, negative cash flows, and eroding equity base.

Income Statement

45Neutral

Balance Sheet

25Negative

Cash Flow

30Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	285.83M	276.31M	158.22M	173.86M	145.70M	30.80M
Gross Profit	113.77M	118.91M	77.32M	88.22M	58.76M	9.04M
EBITDA	-199.78M	-159.83M	-369.37M	-655.75M	-752.27M	-723.49M
Net Income	-333.70M	-540.92M	-590.62M	-768.00M	-846.13M	-702.33M
Balance Sheet
Total Assets	833.03M	987.32M	1.68B	2.15B	2.79B	3.12B
Cash, Cash Equivalents and Short-Term Investments	392.02M	503.28M	762.53M	1.01B	1.39B	1.84B
Total Debt	254.85M	262.67M	422.40M	318.80M	279.13M	147.03M
Total Liabilities	380.71M	430.82M	511.20M	462.26M	437.06M	325.75M
Stockholders Equity	452.32M	556.50M	1.17B	1.68B	2.35B	2.79B
Cash Flow
Free Cash Flow	-111.96M	-78.46M	-348.87M	-413.00M	-613.60M	-634.28M
Operating Cash Flow	-109.52M	-76.85M	-333.44M	-398.42M	-536.72M	-561.20M
Investing Cash Flow	-3.04M	-1.49M	-15.43M	9.90M	-124.08M	-137.13M
Financing Cash Flow	-129.40M	-169.81M	90.49M	275.00K	112.35M	-30.62M

JW (Cayman) Therapeutics Co. Ltd. Technical Analysis

Technical Analysis SentimentNegative

Last Price2.22

Price Trends

50DMA2.37Negative

100DMA2.04Positive

200DMA2.15Positive

Market Momentum

MACD-0.06Positive

RSI40.06Neutral

STOCH20.97Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2126, the sentiment is Negative. The current price of 2.22 is below the 20-day moving average (MA) of 2.60, below the 50-day MA of 2.37, and above the 200-day MA of 2.15, indicating a neutral trend. The MACD of -0.06 indicates Positive momentum. The RSI at 40.06 is Neutral, neither overbought nor oversold. The STOCH value of 20.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2126.

JW (Cayman) Therapeutics Co. Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

HK:2126 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HK:2181	57Neutral	HKD 1.79B	17.80	48.25%	―	88.38%	―
HK:9966	52Neutral	HKD 6.06B	-30.68	-10.27%	―	-31.77%	-177.01%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HK:2126	50Neutral	HKD 925.48M	-2.35	-66.16%	―	67.48%	43.84%
HK:2616	47Neutral	HKD 7.77B	-15.53	-43.54%	―	116.67%	-0.42%
HK:1541	44Neutral	HKD 1.25B	-4.64	-32.32%	―	28.93%	27.27%
HK:2171	39Underperform	HKD 6.32B	-56.08	-9.45%	―	68.12%	81.84%

* Healthcare Sector Average

Performance Comparison

HK:2126 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
HK:2126	JW (Cayman) Therapeutics Co. Ltd.	2.22	-1.82	-45.05%
HK:9966	Alphamab Oncology	6.21	-5.46	-46.79%
HK:2171	CARsgen Therapeutics Holdings Ltd.	10.63	-6.92	-39.43%
HK:2181	Mabpharm Limited	0.43	-0.09	-16.35%
HK:2616	CStone Pharmaceuticals	4.94	-1.28	-20.58%
HK:1541	ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H	2.90	-6.15	-67.96%

JW (Cayman) Therapeutics Co. Ltd. Corporate Events

JW Therapeutics Narrows Interim Loss as Carteyva Sales Jump and Costs Ease

Aug 27, 2026

JW (Cayman) Therapeutics reported interim revenue of RMB111.4 million for the six months to June 30, 2026, up 4.7% year on year, driven almost entirely by Carteyva® sales, which surged 36.9% to RMB111.2 million. While gross profit fell due to th...

JW Therapeutics Sets Board Meeting to Approve Interim 2026 Results

Aug 12, 2026

JW (Cayman) Therapeutics Co. Ltd. has scheduled a board meeting for August 27, 2026, to review and approve its unaudited interim results for the six months ended June 30, 2026. The meeting will also address other business items, signaling routine gov...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 23, 2026

JW (Cayman) Therapeutics Co. Ltd. AI Stock Analysis